LBA33 Maintenance olaparib rechallenge in patients (pts) with ovarian carcinoma (OC) previously treated with a PARP inhibitor (PARPi): Phase IIIb OReO/ENGOT Ov-38 trial
| Autor: | Pujade-Lauraine, E., Selle, F., Scambia, G., Asselain, B., Marmé, F., Lindemann, K., Colombo, N., Madry, R., Glasspool, R.M., Dubot, C., Oaknin, A., Zamagni, C., Heitz, F., Gladieff, L., Rubio-Pérez, M.J., Scollo, P., Blakeley, C., Shaw, B., Ray-Coquard, I.L., Redondo, A. |
|---|---|
| Zdroj: | In Annals of Oncology September 2021 32 Supplement 5:S1308-S1309 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|